manilatimes37m
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Randomized Phase 2 trial evaluating casdozokitug/bevacizumab/toripalimab now open for enrollment - REDWOOD CITY, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: ...
BPGbio Unveils Research on the Identification of Novel Pancreatic Cancer Patient Subtypes at ASCO GI 2025 Paving the Way for Tailored Treatment
BPGbio shares results of Project Survival clinical trial identifying novel pancreatic cancer patient subtypes at ASCO GI 2025 ...